JP2007508326A - Ｈｃｖ感染のための組み合わせ治療 - Google Patents

Ｈｃｖ感染のための組み合わせ治療 Download PDF

Info

Publication number
JP2007508326A
JP2007508326A JP2006534467A JP2006534467A JP2007508326A JP 2007508326 A JP2007508326 A JP 2007508326A JP 2006534467 A JP2006534467 A JP 2006534467A JP 2006534467 A JP2006534467 A JP 2006534467A JP 2007508326 A JP2007508326 A JP 2007508326A
Authority
JP
Japan
Prior art keywords
day
therapeutic combination
administration
sufficient
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006534467A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007508326A5 (enExample
Inventor
エネ・エッテ
ジョン・ジェイ・アラム
ロバート・スティーブン・カウフマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2007508326A publication Critical patent/JP2007508326A/ja
Publication of JP2007508326A5 publication Critical patent/JP2007508326A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006534467A 2003-10-11 2004-10-12 Ｈｃｖ感染のための組み合わせ治療 Pending JP2007508326A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51073303P 2003-10-11 2003-10-11
PCT/US2004/033739 WO2005037274A1 (en) 2003-10-11 2004-10-12 Combination therapy for hcv infection

Publications (2)

Publication Number Publication Date
JP2007508326A true JP2007508326A (ja) 2007-04-05
JP2007508326A5 JP2007508326A5 (enExample) 2007-10-11

Family

ID=34465143

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006534467A Pending JP2007508326A (ja) 2003-10-11 2004-10-12 Ｈｃｖ感染のための組み合わせ治療

Country Status (17)

Country Link
US (1) US20050112093A1 (enExample)
EP (1) EP1670462A1 (enExample)
JP (1) JP2007508326A (enExample)
KR (1) KR20060120037A (enExample)
CN (1) CN1882335A (enExample)
AR (1) AR045870A1 (enExample)
AU (1) AU2004281747A1 (enExample)
BR (1) BRPI0415249A (enExample)
CA (1) CA2541857A1 (enExample)
IL (1) IL174864A0 (enExample)
MX (1) MXPA06004077A (enExample)
NO (1) NO20062104L (enExample)
PE (1) PE20050477A1 (enExample)
RU (1) RU2006115916A (enExample)
TW (1) TW200528104A (enExample)
WO (1) WO2005037274A1 (enExample)
ZA (1) ZA200602912B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011001897A1 (ja) * 2009-06-30 2011-01-06 明治製菓株式会社 難治性のｃ型慢性肝炎の治療のための薬剤及び方法
JP2013060474A (ja) * 2004-10-29 2013-04-04 Vertex Pharmaceuticals Inc Ｖｘ−９５０を含む剤形およびそれらの投与量レジメン

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2268391A1 (en) 1996-10-18 1998-04-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
PE20050374A1 (es) 2003-09-05 2005-05-30 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
US20120201883A1 (en) * 2004-05-21 2012-08-09 Accu-Break Technologies, Inc Antiviral compositons
EP2402331A1 (en) * 2005-08-02 2012-01-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
CA2646229A1 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
WO2008106058A2 (en) * 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
FR2928146B1 (fr) * 2008-02-28 2010-02-19 Saint Gobain Isover Produit a base de fibres minerales et son procede d'obtention.
MY152824A (en) * 2008-09-17 2014-11-28 Boehringer Ingelheim Int Combination of hcv ns3 protease inhibitor with interferon and ribavirin.
JP2012517478A (ja) * 2009-02-12 2012-08-02 バーテックス ファーマシューティカルズ インコーポレイテッド ペグ化インターフェロン、リバビリンおよびテラプレビルを含む、ｈｃｖ組合せ治療剤
EP2459211A1 (en) 2009-07-31 2012-06-06 Medtronic, Inc. Continuous subcutaneous administration of interferon- to hepatitis c infected patients
US8822496B2 (en) 2009-10-30 2014-09-02 Boehringer Ingelheim International Gmbh Dosage regimens for HCV combination therapy
AU2013201406B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CH707030B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Kombinationsbehandlung von DAAs zur Verwendung in der Behandlung von HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
WO2017062840A1 (en) * 2015-10-09 2017-04-13 Trek Therapeutics, Pbc Combination therapy for the treatment of hepatitis c virus
CA3022119A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2017223178A1 (en) * 2016-06-21 2017-12-28 Trek Therapeutics, Pbc Treating viral infections with impdh inhibitors
KR101991365B1 (ko) * 2017-03-14 2019-06-21 국립암센터 C형 간염 바이러스 질환 치료를 위한 리고세르팁의 신규 용도
CN109745315B (zh) * 2019-03-08 2021-04-16 中国农业科学院兰州兽医研究所 一种Merimepodib在制备预防口蹄疫病毒感染的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515453A (ja) * 1998-05-15 2002-05-28 シェリング・コーポレーション 慢性Ｃ型肝炎感染を有する、抗ウイルス処置を受けていない患者における、リバビリンおよびインターフェロンαを含む併用療法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2252465C (en) * 1996-04-23 2007-07-03 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of impdh enzyme
US6824769B2 (en) * 2001-08-28 2004-11-30 Vertex Pharmaceuticals Incorporated Optimal compositions and methods thereof for treating HCV infections
AU2003249659A1 (en) * 2002-05-31 2003-12-19 Schering Corporation Combination therapy for rna virus infections involving ribavirin and impdh inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515453A (ja) * 1998-05-15 2002-05-28 シェリング・コーポレーション 慢性Ｃ型肝炎感染を有する、抗ウイルス処置を受けていない患者における、リバビリンおよびインターフェロンαを含む併用療法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013060474A (ja) * 2004-10-29 2013-04-04 Vertex Pharmaceuticals Inc Ｖｘ−９５０を含む剤形およびそれらの投与量レジメン
WO2011001897A1 (ja) * 2009-06-30 2011-01-06 明治製菓株式会社 難治性のｃ型慢性肝炎の治療のための薬剤及び方法

Also Published As

Publication number Publication date
TW200528104A (en) 2005-09-01
MXPA06004077A (es) 2006-06-27
CN1882335A (zh) 2006-12-20
AU2004281747A1 (en) 2005-04-28
RU2006115916A (ru) 2007-12-10
PE20050477A1 (es) 2005-08-24
CA2541857A1 (en) 2005-04-28
EP1670462A1 (en) 2006-06-21
WO2005037274A1 (en) 2005-04-28
KR20060120037A (ko) 2006-11-24
IL174864A0 (en) 2008-04-13
BRPI0415249A (pt) 2006-12-12
US20050112093A1 (en) 2005-05-26
ZA200602912B (en) 2007-06-27
AR045870A1 (es) 2005-11-16
NO20062104L (no) 2006-05-10

Similar Documents

Publication Publication Date Title
JP2007508326A (ja) Ｈｃｖ感染のための組み合わせ治療
US6299872B1 (en) Combination therapy for chronic hepatitis c infection
US20020127203A1 (en) Ribavirin-pegylated interferon alfa HCV combination therapy
KR19990082084A (ko) 인터페론으로 선행치료한 hcv 환자를 재치료하기 위한 제약학적 조성물
US20110270212A1 (en) Pharmacokinetic control for optimized interferon delivery
KR20120106942A (ko) Ｂｉ２０１３３５, 인터페론 알파 및 리바비린을 포함하는 ｈｃｖ 병용 치료요법을 위한 투여 용법
CN1835765A (zh) 治疗病毒感染的方法
US20150258167A1 (en) New Treatments of Hepatitis C Virus Infection
MXPA00003401A (es) Tratamiento del carcinoma de celula renal.
Zhang Pegylated interferons in the treatment of chronic hepatitis C
US20150139950A1 (en) Alisporivir to treat hepatitis c virus infection
WO2008021536A2 (en) Use of interferon tau for the manufacture of a medicament in combination with interferon-alpha or interferon-beta for reduction of their adverse effects
HK1098359A (en) Combination therapy for hcv infection
JP2004155777A (ja) Ｃ型慢性肝炎治療剤
US20160235808A1 (en) Treatment of Hepatitis C Virus Infection with Alisporivir
HK1008811A (en) Combination therapy for chronic hepatitis c infection
MXPA06001695A (en) Method of treating viral infections
WO2013138064A1 (en) Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070821

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101214

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110705